PDE5 inhibitors: Targeting erectile dysfunction in diabetics

Current Opinion in Pharmacology

Volumn 11, Issue 6, 2011, Pages 683-688

  Francis, Sharron H ^a   Corbin, Jackie D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ATORVASTATIN; CALCIUM; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROPIONYLCARNITINE; SILDENAFIL; TADALAFIL; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA1; UDENAFIL; VARDENAFIL;

ARTICLE; CALCIUM CELL LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PENILE BLOOD FLOW; PENILE FIBROSIS; PENIS ERECTION; PRIORITY JOURNAL; SMOOTH MUSCLE RELAXATION; TUNICA MEDIA; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 82255191651     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.08.004     Document Type: Review

References (50)

1. C. Gazzaruso, S.B. Solerte, A. Pujia, A. Coppola, M. Vezzoli, F. Salvucci, C. Valenti, A. Giustina, and A. Garzaniti Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease J Am Coll Cardiol 51 2008 2040 2044 (Pubitemid 351689055)
2. J. Hidalgo-Tamola, and K. Chitaley Type 2 diabetes mellitus and erectile dysfunction J Sex Med 6 2009 916 926
3. K. Garcia-Malpartida, R.M. Lozano, A.J. Fernandez, M.J. Gomez Marinez, E.S. Izquierdo, V.M. Victor, M.R. Barajas, D.S. Cervera, and A. Hernandez Mijares Relationship between erectile dysfunction and silent myocardial ischemia in type 2 diabetic patients with no known macrovascular complications J Sex Med 8 2011 2606 2616
4. M. Fukui, M. Tanaka, H. Okada, H. Iwase, Y. Mineoka, T. Senmaru, M. Ohnishi, S.I. Mogami, Y. Kitagawa, and M. Yamazaki Five-item version of the International Index of Erectile Function correlated with albuminuria and subclinical atherosclerosis in men with type 2 diabetes J Atheroscler Thromb 2011
5. G. Jackson, N. Boon, I. Eardley, M. Kirby, J. Dean, G. Hackett, P. Montorsi, F. Monorsi, C. Vlachopoulos, and R.A. Kloner Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus Int J Clin Pract 64 2010 848 857
6. L.S. Malavige, and J.C. Levy Erectile dysfunction in diabetes mellitus J Sex Med 6 2009 1232 1247
7. S.H. Francis, and 1. Corbin JD: Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction Urol Clin North Am 32 2005 419 429 (Pubitemid 41607530)
8. S.H. Francis, J.A. Busch, and J.D. Corbin Cyclic GMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action Pharmacol Rev 62 2010 525 563
9. S. Gur, P.J. Kadowitz, L. Gurkan, S. Chandra, S.Y. Dewitt, A. Harbin, S.C. Sikka, K.C. Agrawal, and W.J. Hellstrom Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil BJU Int 106 2010 78 83
10. J. Angulo, R. Gonzalez-Corrochano, P. Cuevas, A.J. Fernandez, J.M. LaFuente, F. Rolo, A. Allona, and I. Saenz de Tejada Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries J Sex Med 7 2010 758 768
11. S.H. Francis, M.A. Blount, and J.D. Corbin Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions Physiol Rev 91 2011 651 690
12. P. Hedlund, A. Aszodi, A. Pfeifer, P. Alm, F. Hofmann, M. Ahmad, R. Fassler, and K.E. Andersson Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice Proc Natl Acad Sci U S A 97 2000 2349 2354 (Pubitemid 30134072)
13. N. Shukla, G. Rossoni, M. Hotston, A. Sparatore, P. DelSoldato, V. Tazzari, R. Persad, G.D. Angelini, and J.Y. Jeremy Effect of hydrogen sulphide-donating sildenafil (ACS6) on erectile function and oxidative stress in rabbit isolated corpus cavernosum and in hypertensive rats BJU Int 103 2009 1522 1529
14. J. Arana Rosainz Mde, M.O. Ojeda, J.R. Acosta, L.C. Elias-Calles, N.O. Gonzalez, O.T. Herrera, C.T. Garcia Alvarez, E.M. Rodrigues, M.E. Baez, and E.A. Seijas Imbalanced low-grade inflammation and endothelial activation in patients with type 2 diabetes mellitus and erectile dysfunction J Sex Med 8 2011 2017 2030
15. M.F. Usta, M. Kendirci, S. Gur, N.A. Foxwell, T.J. Bivalacqua, S. Cellek, and W.J. Hellstrom The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment J Sex Med 3 2006 242 250
16. Y. Ishibashi, T. Matsui, M. Takeuchi, and S. Yamaghish Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP Clin Exp Med 11 2011 131 135
17. N.O. Rizzo, E. Maloney, M. Pham, I. Luttrell, H. Wessells, S. Tateya, G. Daum, P. Handa, M. Schwartz, and F. Kim Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding Arterscler Thromb Vasc Biol 30 2010 758 765
18. A.L. Burnett, T.D. Strong, B.J. Trock, L. Jin, T.J. Bivalacqua, and B. Musicki Serum biomarker measurements of endothelial function and oxidative stress after dailing dosing of sildenafil in type 2 diabetic men with erectile dysfunction J Urol 181 2009 245 251
19. S. Morano, E. Mandosi, M. Fallarino, A. Gatti, C. Tiberti, M. Sensi, L. Gandini, B. Bchetti, L. Lenti, and E.A. Jannini Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind placebo-controlled study Eur Urol 52 2007 1768 1776 (Pubitemid 350052399)
20. A. Konstantinopoulos, K. Giannitsis, A. Athanasopoulos, D. Spathas, and P. Perimenis The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction Expert Opin Pharmacother 10 2009 155 160
21. R. Ritchie, and M. Sullivan Endothelins and erectile dysfunction Pharmacol Res 63 2011 496 501
22. A. Aversa, C. Vitale, M. Volterrani, A. Fabbri, G. Spera, M. Fini, and G.M. Rosano Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes Diabet Med 25 2008 37 44
23. P.A. Jansson, G. Murdolo, L. Sjogren, B. Nystrom, M. Sjostrand, L. Strindberg, and P. Lonnroth Tadalafil increases muscle capillary recruitment and forearm glucose uptake in women with type 2 diabetes Diabetologia 53 2010 2205 2208
24. C. Mammi, D. Pastore, M.F. Lombardo, F. Ferrelli, M. Caprio, C. Consoli, M. Tesauro, L. Gatta, M. Fini, and M. Federici Sildenafil reduces insulin-resistance in human endothelial cells PLoS One 6 2011 e14542
25. M.G. Ferrini, H. Davila, I. Kovanecz, S. Sanchez, N.F. Gonzalez-Cadavid, and J. Rajfer Long-term continuous treatment with vardenafil prevents fibrosis and preserves smooth muscle content in the rat corpora cavernosa after bilateral cavernosal nerve transaction Urology 68 2006 429 435 (Pubitemid 44175524)
26. N.F. Gonzalez-Cadavid Mechanisms of penile fibrosis J Sex Med 6 2009 353 362
27. I. Kovanecz, G. Nolazco, M.G. Ferrini, J.E. Tobili, S. Heydarkhan, D. Vernet, J. Rajfer, and N.F. Gonzalez-Cadavid Early onset of fibrosis within the arterial media in a rat model of type 2 diabetes mellitus with erectile dysfunction BJU Int 103 2009 1396 1404
28. N.F. Gonzalez-Cadavid, and J. Rajfer Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy Nat Rev Urol 7 2010 215 221
29. B. Hohenstein, C. Daniel, S. Wittmann, and C. Hugo PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis Nephrol Dial Transplant 23 2008 3427 3436
30. Y. Kuno, M. Iyoda, T. Shibata, Y. Hirai, and T. Akizawa Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima fatty rats Br J Pharmacol 162 2011 1389 1400
31. T. Nagayama, S. Hsu, M. Zhang, N. Koitabashi, D. Bedja, K.L. Gabrielson, E. Takimoto, and D.A. Kass Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload J Am Coll Cardiol 53 2009 207 215
32. L. Kang, J.E. Ayala, R.S. Lee-Young, Z. Zhang, F.D. James, P.D. Neufer, A. Pozzi, M.M. Zutter, and D.H. Wasserman Diet-induced muscle insulin resistance is associated with extracellular matrix remodeling and interaction with integrin alpha2beta1 in mice Diabetes 60 2011 416 426
33. E. Yohannes, J. Chang, M.T. Tar, K.P. Davies, and M.R. Chance Molecular targets for diabetes mellitus-associated erectile dysfunction Mol Cell Proteomics 9 2010 565 578
34. P. Dorsey, C. Keel, M. Klavens, and W.J. Hellstrom Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction Expert Opin Pharmacother 11 2010 1109 1122
35. H. Awad, A. Salem, A. Gadalla, N.A. El Wafa, and O.A. Mohamed Erectile function in men with diabetes type 2: correlation with glycemic control Int J Impot Res 22 2010 36 39
36. O. Yaman, M. Akand, S. Gursoy, M.F. Erdogan, and K. Anafarta The effect of diabetes mellitus treatment and good glycemic control on the erectile function in men with diabetes mellitus-induced erectile dysfunction: a pilot study J Sex Med 3 2006 344 348
37. R.C. Rosen, R.R. Wing, S. Schneider, T.A. Wadden, G.D. Foster, D.S. West, A.E. Kitabchi, F.L. Brancati, B.J. Maschak-Carey, and J.L. Bahnson Erectile dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the Look AHEAD trial J Sex Med 6 2009 1414 1422
38. G. Corona, E. Mannucci, G. Forti, and M. Maggi Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes? Int J Androl 32 2009 431 441
39. X.H. Zhang, S. Filippi, A. Morelli, L. Vignozzi, M. Luconi, S. Donati, G. Forti, and M. Maggi Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes J Sex Med 3 2006 253 264
40. E. Vicari, V.S. Lavignera, R. Condorelli, and A.E. Calogero Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process Int Soc Sex Med 7 2009 1247 1253
41. A. Morelli, A.K. Chavalmane, S. Filippi, B. Fibbi, E. Silvestrini, E. Sarchielli, X.H. Zhang, L. Vignozzi, G.B. Vannelli, and G. Forti Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation J Sex Med 6 2009 91 106
42. F. Dadkhah, M.R. Safarinejad, M.A. Asgari, S.Y. Hosseini, A. Lashay, and E. Amini Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil Int J Impot Res 22 2010 51 60
43. A.J. Bella, L. DeYoung, M. al-Numi, and G.B. Brock Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications Eur Urol 52 2007 990 1005 (Pubitemid 47334787)
44. Y. Vardi, B. Appel, Y. Ofer, I. Greunwald, L. Dayan, and G. Jacob Effect of chronic sildenafil treatment on penile endothelial function: a randomized, double-blind, placebo controlled study J Urol 182 2009 2850 2855
45. L. DeYoung, E. Chung, J.R. Kovac, W. Romano, and G.B. Brock Daily use of sildenafil improves endothelial function in type 2 diabetic men J Androl 2011
46. C. Foresta, L. De Toni, A. Biagioli, F. Ganz, S. Magagna, and N. Caretta Increased levels of osteocalcin-positive endothelial progenitor cells in patients affected by erectile dysfunction and cavernous atherosclerosis J Sex Med 7 2010 751 757
47. K. Park, K.S. Ryu, W.J. Li, S.W. Kim, and J.S. Paick Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smoth muscle by potentiating Akt signaling in a rat model of diabetic erectile dysfunction Eur Urol 53 2008 1282 1288
48. G. Liu, X. Sun, Y. Dai, F. Zheng, D. Wang, Y. Huang, J. Bian, and C. Deng Chronic administration of sildenafil modified the impaired VEGF system and improved the erectile function in rats with diabetic erectile dysfunction J Sex Med 7 2010 3868 3878
49. S. La Vignera, R. Condorelli, E. Vicari, R. D'Agata, and A. Calogero Endothelial antioxidant compound prolonged the endothelial anti-apoptotic effects registered after tadalafil treatment in patients with arterial erectile dysfunction J Androl 2011
50. M. Conti, and J. Beavo Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling Annu Rev Biochem 6 2007 481 511